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doi:10.1016/j.jtcvs.2004.03.007432 The Journal of Thoracic and CardioObjective: Although the beneficial effect of aspirin prescription after coronary
surgery has been established, the efficacy of clopidogrel has never been com-
pared with that of aspirin in the critical early postoperative period. We therefore
conducted a prospective, double-blind, randomized controlled trial to compare
the efficacies of these antiplatelet regimens.
Methods: Patients undergoing elective primary coronary artery bypass surgery were
invited to participate. After the operation, patients were randomized to receive 100
mg aspirin, 325 mg aspirin, or 75 mg clopidogrel tablets daily for 5 days. Our
primary outcome measure was platelet aggregation on day 5, expressed as percent-
age of baseline. Assessment of platelet aggregation was undertaken with the
technique of Born.
Results: From September 2002 to July 2003, a total of 54 patients were randomized
into the study. There were 2 self-withdrawals and 2 protocol violations, leaving 50
patients for analysis, 34 in the aspirin group and 16 in the clopidogrel arm.
Compared with baseline, the mean percentage aggregations with collagen on day 5
were 56% for aspirin and 99% for clopidogrel. The mean difference between the two
arms was 42% (95% confidence interval 27%-56%) in favor of aspirin. At the same
time point, the effective concentration to inhibit 50% aggregation in the samples
from patients randomly assigned to receive clopidogrel were not raised for our entire
panel of agonists (changes of 0.04 g/L for collagen, 0.01 mol/L for epineph-
rine, and 0.02 mol/L for adenosine diphosphate).
Conclusion: Clopidogrel, unlike aspirin, did not inhibit platelet aggregation in the
first 5 postoperative days and therefore should not be used as a sole antiplatelet
agent early after coronary surgery.
Antiplatelet therapy after coronary bypass is simple to administer,cost-effective, and critical. Although the beneficial effects ofaspirin in the prevention of graft occlusion has been well estab-lished, controversies have emerged regarding the optimal aspirindose1 and indeed the ideal antiplatelet agent. It has been reportedthat low-dose aspirin (100 mg) does not effectively inhibit platelet
function after coronary surgery,2 and a subanalysis from the CAPRIE study (Clo-
pidogrel versus Aspirin in Patients at Risk of Ischemic Events) reported striking
reductions in the risk of recurrent ischemic events for patients receiving clopidogrel
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led us to investigate the effects of low- and medium-dose
aspirin and clopidogrel (as an alternative antiplatelet agent)
on inhibition of platelet function after coronary artery by-
pass surgery.
Methods
We report here the results of an analysis based on interim data
from a local research ethics committee–approved prospective,
randomized trial currently in progress at our institution. We
planned to recruit 108 patients (36 in each of the three arms), with
an interim analysis planned after 54 patients (18 in each arm). We
aimed to be able to detect a difference of 30% in postoperative
platelet aggregation at day 5 (expressed as a percentage of preop-
erative values) between any two arms. If this difference was found
to be statistically significant (at 2% level), the inferior arm would
be stopped. At the analysis stage there would be at least 90%
power to detect a difference of at least 1.5 SDs.
All patients undergoing elective primary coronary artery by-
pass surgery were invited to participate, and we excluded patients
if they did not discontinue antiplatelet therapy a week before
surgery, had contraindications to aspirin or clopidogrel, were re-
ceiving other medications that interact with aspirin or clopidogrel,
underwent surgery without cardiopulmonary bypass, received
platelet transfusion during the operation or within the first 24
hours, or could not be extubated in the first 24 hours.
No restrictions were placed on operative technique, and car-
diopulmonary bypass was driven by a roller pump with a mem-
brane oxygenator with an arterial (but no leukocyte) filter, as
Figure 1. Tristandard at our institution. Temperature on bypass ranged between
The Journal of Thoraci30°C to 37°C. Tranexamic acid (but not aprotinin) was adminis-
tered routinely.
On the first postoperative morning, patients were randomly
assigned to receive one of the following identically encapsulated
treatments: 100 mg aspirin, 325 mg aspirin, or 75 mg clopidogrel
daily for 5 days. Randomization was undertaken by the pharmacy
into treatment allocation blocks of 6.
Our primary outcome measure was percentage aggregation on
day 5 (2 hours after drug administration) expressed as percentage
of baseline, with 1.1 g/L collagen as an agonist. Assessment of
platelet aggregation was undertaken according to the technique of
Born.4 Secondary outcome measures were effective concentrations
of Horm collagen, adenosine diphosphate (ADP), and epinephrine
on day 5 required to produce 50% aggregation (EC50) relative to
baseline.
For this analysis, patients were grouped according to treatment
allocation of aspirin or clopidogrel. Categoric data are presented as
frequency (percentage), and continuous data are given as mean 
SD or median with interquartile range. Comparisons of categoric
data between the two groups were made with the Fisher exact test
or Pearson 2 test. Continuous data were compared with the
Student t test or the Mann-Whitney test as appropriate.
Results
From September 2002 to July 2003, a total of 123 patients
were invited to participate, 72 of whom consented to par-
ticipate in the study. After enrollment, 54 patients were
randomly allocated into study groups. Four patients were
w diagram.al flowithdrawn, 2 as self-withdrawals and 2 because of protocol
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leaving 50 patients for analysis. In total, 34 remained in the
aspirin arms and 16 in the clopidogrel arm (Figure 1).
The patients were well matched for baseline character-
istics, in particular for the use of atorvastatin (Table 1). For
patients randomly assigned to receive clopidogrel, the mean
 SD aggregation with 1.1 g/L collagen as an agonist on
day 5 was 99%  15% relative to baseline. At the same
time, the EC50 concentrations were not raised versus base-
line for the entire panel of agonists (0.04 g/L for colla-
gen, 0.01 mol/L for epinephrine, and 0.02 mol/L for
ADP).
For aspirin, the mean aggregation with 1.1 g/L collagen
as an agonist was 56%  15% relative to baseline on day 5.
The mean difference in aggregation between the two groups
at this time point was 42% (95% confidence interval 27%-
56%) in favor of aspirin. Further results in both treatment
arms are presented in Table 2.
Discussion
There is no stimuli as potent as cardiopulmonary bypass for
provoking an inflammatory response. The magnitude of the
surgery and exposure to the extracorporeal circuit result in
such marked platelet activation that normal pharmacologic
response to antiplatelet agents cannot be assumed under
these conditions. In healthy volunteers, inhibition of platelet
aggregation by clopidogrel occurs 1 hour after dosing, with
a mean percentage inhibition of 48.1% by day 5 with 5
mol/L ADP.5 However, we found no evidence of inhibi-
tion of platelet aggregation by clopidogrel with either ADP,
collagen, or epinephrine by day 5 after coronary surgery.
With respect to a recent suggestion regarding the inter-
6
TABLE 1. Patient characteristics
Aspirin Clopidogrel P value
Sample size 36 18
Age (y, mean  SD) 65 8 64 8 .67
Mean height, m (SD) 1.7 0.1 1.7 0.1 .28
Mean weight, kg (SD) 86 15 82 11 .35
Male sex (No.) 35 (97%) 17 (94%) .61
Diabetes (No.) 6 (17%) 5 (28%) .34
Hypercholesterolemia (No.) 33 (92%) 16 (89%) .74
Hypertension (No.) 19 (53%) 8 (44%) .56
Current smoker (No.) 2 (6%) 3 (17%) .18
No. of grafts (median, IQR) 4 (3–4) 3 (3–4) .44
Bypass (min, median, IQR) 72 (63–85) 64 (55–78) .14
Cholesterol lowering therapy (No.)
None 4 (11%) 1 (6%)
Atorvastatin 12 (33%) 8 (44%)
Simvastatin 10 (28%) 3 (17%) .70
Pravastatin 9 (25%) 6 (33%)
Fluvastatin 1 (3%) 0 (0%)
IQR, Interquartile range.action between atorvastatin and clopidogrel , we report that
434 The Journal of Thoracic and Cardiovascular Surgery ● Septthe absence of platelet inhibition was observed uniformly in
all patients in the clopidogrel arm regardless of whether
they were receiving atorvastatin, simvastatin, or pravastatin.
Unfortunately, our study was on the comparative effica-
cies of three antiplatelet regimens in the early postoperative
period and was not focused on why clopidogrel would be
ineffective, which was an unexpected finding on interim
analysis. Although we assume that the inflammatory re-
sponse generated from cardiopulmonary bypass is impor-
tant, it is impossible to discern whether our findings could
be explained by inadequate clopidogrel dosage under ad-
verse conditions, high platelet turnover, platelet receptor
dysregulation, or the effects of trauma independent of car-
diopulmonary bypass. The most likely explanation is an
interaction of factors, and clearly other studies are required
to provide further insight to the weight of each individual
contribution or to offer alternative explanation.
Clinical Implications
What does matter is the timing of antiplatelet administration
that is critical within the first week after surgery for the
effects of improved graft patency and survival.7 An early
trial revealed that the frequency of new graft occlusions was
not improved by aspirin after the first 9 days.8 More pre-
cisely, we assume that the effects of an antiplatelet drug
need to be evident within this time (if it is the antiplatelet
action that is important in the preservation of graft patency).
If 75 mg clopidogrel were to be used as the sole antiplatelet
agent, this would be akin to giving patients a placebo in the
first week, as previous work suggested that the antiplatelet
effects of clopidogrel commences between the ninth and
28th postoperative days.9
Although the risk of recurrent ischemic events may be
reduced by clopidogrel administration in patients with pre-
vious cardiac surgery, it is important to note that clopidogrel
was not started immediately after surgery in the CAPRIE
study, and patients could have received aspirin right up to
entry into the trial. The results of our trial cannot be extrap-
olated beyond the early postoperative period, and we do not
suggest that clopidogrel is ineffective in the long term.
However, neither can the beneficial results of clopidogrel
(as reported by CAPRIE) be safely extrapolated to the early
postoperative phase. We have demonstrated the inefficacy
of clopidogrel in this critical time frame. In view of the
interim data, the clopidogrel arm has been withdrawn from
our trial as we continue to evaluate the efficacy of low-
versus medium-dose aspirin.
Conclusion
Because of its inability to inhibit platelet aggregation, clo-
pidogrel at a dose of 75 mg or less should not be used as the
sole antiplatelet agent early after coronary artery bypass
surgery.
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